FIG 4.

D1329A replication is significantly increased by the addition of PARP inhibitors. (A and B) BMDMs (A) and 17Cl-1 cells (B) were treated with the indicated compounds, and, at 24 h, cell viability was measured using an MTT assay as described in Materials and Methods. (C and D) WT BMDMs (C) and 17Cl-1 cells (D) were infected with WT, N1347A, or D1329A and then treated with 0.25% dimethyl sulfoxide (DMSO), 10 μM olaparib (2281), or 10 μM XAV-939 as described in Materials and Methods. Progeny virus was collected at the indicated time points, and virus titers were determined by plaque assay. The data in panels A to D show one experiment representative of two independent experiments, with n = 4 (A and B) or n = 3 (C and D) for each experiment.